Heron Therapeutics
HRTX
196 hedge funds and large institutions have $3.33B invested in Heron Therapeutics in 2018 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 66 increasing their positions, 54 reducing their positions, and 11 closing their positions.
418% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 11
49% more capital invested
Capital invested by funds: $2.24B → $3.33B (+$1.1B)
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
29% more funds holding
Funds holding: 152 → 196 (+44)
22% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 54
3.57% less ownership
Funds ownership: 125.57% → 122% (-3.6%)
61% less call options, than puts
Call options by funds: $41.6M | Put options by funds: $107M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$94.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$82.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.2M |
| 4 |
BlackRock
New York
|
+$32.9M |
| 5 |
BM
Bridger Management
New York
|
+$22.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$68.5M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$45M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$34.9M |
| 4 |
BC
Broadfin Capital
New York
|
-$33.8M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$27.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
201
Athanor Capital
New York
| – | -$966K | -35,000 | Closed |
|
202
DZ Bank
Frankfurt Am Main,
Germany
| – | -$361K | -13,062 | Closed |
|
203
Marshall Wace
London,
United Kingdom
| – | -$334K | -12,100 | Closed |
|
|
FANJ
204
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$8K | -300 | Closed |
|
|
APP
205
Avantax Planning Partners
Dubuque,
Iowa
| – | -$4K | -160 | Closed |
|
|
WAS
206
Winch Advisory Services
Appleton,
Wisconsin
| – | -$3K | -100 | Closed |
|
HRTX Hedge Fund Activity: Q2 2018 in Review
196 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2018, worth a combined $3.33B — up 49% from $2.24B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new HRTX positions and 11 closed out — a net gain of 46 holders — while 66 added to existing stakes and 54 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $94.2M. The largest seller was Janus Henderson Group, cutting an estimated $68.5M.
- 196 institutional investors held Heron Therapeutics (HRTX) as of Q2 2018, up from 152 in Q1 2018.
- Funds reported $3.33B of Heron Therapeutics stock for Q2 2018, up 49% quarter-over-quarter.
- 57 funds opened new Heron Therapeutics positions in Q2 2018 and 11 closed out, a net change of +46 holders.
- The largest Heron Therapeutics buyer in Q2 2018 was Fidelity International, an estimated $94.2M added.
- The largest Heron Therapeutics seller in Q2 2018 was Janus Henderson Group, an estimated $68.5M sold.
Based on aggregated 13F filings for Q2 2018.